Advertisement
News
Advertisement

Acceleron DMD drug gets orphan drug status

Thu, 08/19/2010 - 9:32am
Mass High Tech: The Journal of New England Technology

Acceleron Pharma Inc. has won financial incentives and enhanced protection from generic competition, for its drug candidate to treat Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength.

The Cambridge-based biotechnology company says the U.S. Food and Drug Administration granted orphan status for the drug, called ACE-031, after determining it could meet an unmet medical need for patients of a rare disease.

The company has also received fast track status for the potential therapy, meaning that the FDA will shorten the time it takes to make a decision on approval, once the drug target is submitted. The drug target is currently being studied in a Phase 2 clinical trial for this indication.

Once a drug candidate has orphan status, the FDA may provide grant funding towards clinical trial costs, tax advantages, FDA user-fee benefits and seven years of market exclusivity in the U.S. following drug approval by the FDA. 

DMD primarily affects boys and occurs in approximately 1 in every 3,500 live male births. Few patients survive beyond their late-20s when their heart and respiratory muscles weaken and eventually fail.

 

 

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading